Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 85, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2020.106607
Keywords
Osteoarthritis; Curcumin; Clinical trial; Th17; Treg; BAFF receptors
Categories
Funding
- Mashhad University of Medical Sciences, Mashhad, Iran [961606]
Ask authors/readers for more resources
Osteoarthritis (OA) routinely is known as a multifactorial degenerative joint disease. This trial aimed to assess the curcumin (an active element of turmeric) effects on the immune responses in OA patients. Thirty patients were selected according to the American College of Rheumatology (ACR) criteria and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and equally divided into the two groups; intervention (received Sinacurcumin (R) 80 mg daily) and placebo, followed for 3 months. In the intervention group, our data showed a noticeably decrease in Visual Analog Score (VAS), C-reactive protein (CRP), CD4(+) and CD8(+) T cells, Th17 cells and B cells frequency. Additionally, Treg cells indicated a significant increase and Treg/Th17 cells ratio showed a meaningfully shifted toward Treg lymphocytes. In conclusion, our data indicated that clinical manifestation was ameliorated considerably following the administration of curcumin. Moreover, our data demonstrated the immunomodulatory effects of curcumin in OA patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available